Drs Kathy D. Miller and Heather A. Parsons explore the complexities and evolving strategies in managing HER2+ oligometastatic breast cancer, tackling curative intent, treatment duration, and the promise of emerging biomarkers.

Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1001335. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.

Resources

Breast Cancer and HER2 https://emedicine.medscape.com/article/1689966-overview

De Novo Oligometastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/37607325/

A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer https://pubmed.ncbi.nlm.nih.gov/30233772/

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108) https://pubmed.ncbi.nlm.nih.gov/34995128/

Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer: A Retrospective Multicenter Study https://pubmed.ncbi.nlm.nih.gov/34778049/

NRG-BR002: A Phase IIR/III Trial of Standard of Care Systemic Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Resection (SR) for Newly Oligometastatic Breast Cancer (NCT02364557) https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.1007

Systemic Therapies for HER2-Positive Advanced Breast Cancer https://pubmed.ncbi.nlm.nih.gov/38201451/

Oligometastatic Breast Cancer and Metastasis-Directed Treatment: An Aggressive Multimodal Approach to Reach the Cure https://pubmed.ncbi.nlm.nih.gov/36950272/

Circulating Tumor Biomarkers in Early-Stage Breast Cancer: Characteristics, Detection, and Clinical Developments https://pubmed.ncbi.nlm.nih.gov/37941557/

Minimal Residual Disease (MRD) Detection in Solid Tumors Using Circulating Tumor DNA: A Systematic Review https://pubmed.ncbi.nlm.nih.gov/37636270/